Brian Kelly, DO
Cardiovascular Disease · Powell, WYNPI 1811985112
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,104 of the $3,750 with a category attached, or 82.8%. It is spread thinly across 40 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Among cardiovascular disease clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$639
- Novartis$384
- Johnson & Johnson$244
- Abbott$239
- Amgen$229
- Pfizer$200
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,10483%
- Education$70%
- Gifts$63917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tosoh Bioscience, Inc. | 1 | $639 |
| Novartis | 19 | $384 |
| Johnson & Johnson(2 entities) | 10 | $244 |
| Abbott | 7 | $239 |
| Amgen | 14 | $229 |
| Pfizer | 11 | $200 |
| Stryker | 4 | $167 |
| Abiomed | 6 | $167 |
| Sanofi-aventis U.S. LLC | 10 | $164 |
| Actelion Pharmaceuticals US, Inc. | 9 | $133 |
| E.r. Squibb & Sons, L.L.C. | 6 | $116 |
| Boston Scientific | 3 | $99 |
| Bayer | 5 | $99 |
| Boehringer Ingelheim | 4 | $97 |
| Lundbeck LLC | 5 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $60 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Imperative Care, Inc | 1 | $50 |
| Novo Nordisk | 2 | $49 |
| United Therapeutics Corporation | 3 | $42 |
| Merck | 2 | $38 |
| Edwards Lifesciences | 3 | $37 |
| Siemens Medical Solutions USA, Inc. | 2 | $33 |
| AstraZeneca | 2 | $30 |
| Cvrx, Inc. | 2 | $30 |
| Angiodynamics, Inc. | 1 | $29 |
| Vifor Pharma, Inc. | 2 | $29 |
| Kerecis Limited | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| GE HealthCare | 1 | $19 |
| Braemar Manufacturing, LLC | 1 | $16 |
| Philips North America LLC | 1 | $13 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $11 |
| Amarin Pharma, Inc. | 1 | $11 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TSH3G, AIA-PACK$639
- TSH3G, AIA-PACK Calibrator Set$639
- PRINTER PAPER, THERMAL, (1 roll) AIA$639
- XARELTO$119
- ESPRIT$104
How this compares
$3,750 in reported general payments places this provider in the 90th percentile of 22 cardiovascular disease providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $96,426 |
| XareltoRivaroxaban | 43 | $32,709 |
| EntrestoSacubitril/Valsartan | 13 | $17,328 |
| Valsartan | 54 | $1,486 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 26 | $1,050 |
| Metoprolol Succinate | 78 | $848 |
| Spironolactone | 63 | $559 |
| Potassium Chloride | 20 | $436 |
| Rosuvastatin Calcium | 34 | $354 |
| Atorvastatin Calcium | 35 | $277 |
| Losartan Potassium | 25 | $238 |
| Carvedilol | 30 | $236 |
| Amiodarone Hcl | 12 | $193 |
| Metoprolol Tartrate | 39 | $175 |
| Lisinopril | 31 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $200 | $96,426109 claims |
| Johnson & JohnsonXarelto | $244 | $32,70943 claims |
| NovartisEntresto | $384 | $17,32813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 cardiovascular disease providers in Wyoming.
Other cardiovascular disease in Powell
- Michel SkafCasper$15K
- David GonzalezAfton$6K
- Robert NovickCasper$4K
- Adrian FlutureCasper$3K
- Smitha NeerukondaCheyenne$3K
- Michael BrennanSheridan$3K
- William BrannEvanston$2K
- Thomas EdwardsCody$2K
- Allan WicksCasper$1K
- Isheeka EdwardsCheyenne$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.